Molecular signatures of chronic antibody-mediated rejection in human liver transplants

*Bastian Engel[1], *Ahmed Alaswad[2, 3], *Alejandro Campos-Murguia[1], Martijn Zoodsma[2, 3], Anne Klingbeil[1], Kinan Chihab[1], Emily A. Bosselmann[1], Sophia Heinrich[1], Björn Hartleben[4], Danny D. Jonigk[4, 5, &], Murielle Verboom[6], Michael Hallensleben[6], Robert Geffers[7], Christine S Falk[8], Sergej Ruff[9], Chris Lauber[9, 10], Emilie Toft Skovgaard[11], Morten Karsdal[11], Diana Julie Leeming[11], Heiner Wedemeyer[1], Cheng-Jian Xu[2, 3], Elmar Jaeckel[1, #], +Yang Li[2, 3, 12, 13, 14], +Richard Taubert[1]

* authors share first authorship

+ authors share last authorship

Orcid IDs:

Bastian Engel: 0000-0002-0972-3454

Alejandro Campos-Murguia: 0000-0002-2178-302X

Elmar Jaeckel: 0000-0003-4108-7192

Richard Taubert: 0000-0001-9270-2496

Ahmed Alaswad: 0000-0003-1770-1332

Yang Li: 0000-0003-4022-7341

Robert Geffers: 0000-0003-4409-016X

Martijn Zoodsma: 0000-0003-3636-2209

Murielle Verboom: 0000-0001-8260-2045

Cheng-Jian Xu: 0000-0003-1586-4672

Sergej Ruff: 0009-0000-8264-6347

Chris Lauber: 0000-0002-2265-2953

Christine S Falk: 0000-0003-1376-7318

Emilie Toft Skovgaard: 0009-0002-3875-488X

Morten Karsdal: 0000-0001-5026-8740

Diana Julie Leeming: 0000-0002-4256-140X

[1] Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany

[2] Department of Computational Biology for Individualised Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany

[3] TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany

[4] Institute for Pathology, Hannover Medical School, Hannover, Germany

[5] Institute of Pathology, RWTH University of Aachen, Aachen, Germany.

[6] Institute for Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany

[7] Research Group Genome Analytics, Helmholtz Centre for Infection Research, Braunschweig, Germany

[8] Institute of Transplant Immunology, Hannover Medical School (MHH), Hannover, Germany; German Centre for Infection Research, TTU-IICH Hannover, Hannover, Germany

[9] Institute for Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, a joint venture between the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany

[10] Cluster of Excellence 2155 RESIST, Hannover, Germany

[11] Nordic Bioscience A/S, Herlev, Denmark

[12] Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands

[13] Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany

[14] Lower Saxony center for artificial intelligence and causal methods in medicine (CAIMed), Hannover, Germany

[&] Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH) of the German Center for Lung Research (DZL), Hannover, Germany.

[#] Current address: Ajmera Transplant Center, Toronto General Hospital, United Health Network, University of Toronto, Toronto, Canada

Corresponding author:

Prof. Dr. Richard Taubert; Hannover Medical School; Dept. of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology; Carl-Neuberg-Straße 1; 30625 Hannover; Germany.

Tel.: +49-511-532-6766; taubert.richard@mh-hannover.de

Keywords: donor-specific anti-HLA antibodies, T cell-mediated rejection; tumor necrosis factor; interferon gamma; allograft rejection; liver transplantation; RNA-sequencing; chronic rejection; ductopenia

Word count Main Text including Abstract, References, Tables and Figure Legends: 5936

Word count Abstract: 259

Number of Figures: 4

Number of Tables: 2

Financial support: The work was supported by grants from the German Research Foundation (SFB738 project Z2; EJ)), the Transplantation Center Project 19_02 and HiLF II from Hannover Medical School (RT) and the Transplantation Center Project ZN3369 from Hannover Medical School/The Ministry of Science and Culture of the State of Lower Saxony (BE). RT was supported by the Core 100 advanced clinician scientist program from Hannover Medical School. BE was supported by the PRACTIS – Clinician Scientist program of Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3). ACM was supported by the DAAD Research Grants – One-year grants for doctoral Candidates, 2023/2024 (57645447). KC was supported by the Else Kröner-Fresenius Stiftung (KlinStrucMed programme). This work was supported by the Radboud University Medical Centre Hypatia Grant, an ERC Starting Grant, grant agreement 948207 (ModVaccine), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2155 - project number 390874280 (YL, CL), and the Lower Saxony Center for AI and Causal Methods in Medicine (CAIMed) grant funded by the Ministry of Science and Culture of Lower Saxony with funds from the program zukunft.niedersachsen of the VolkswagenStiftung (all to YL). Nordic Bioscience supported the study by measuring extracellular matrix proteins.

Conflict of interest: ESK, MK, and DJL are employed at Nordic Bioscience. MK and DJL hold stocks in Nordic Bioscience. All other authors have nothing to declare with regard to this manuscript.

Author contributions to manuscript: Study concept and design: BE, EJ, RT. Acquisition of data: BE (overall data management), ACM (validation cohort), AK and KC (training cohort), BH & DDJ (histopathology), ETS (ECM markers), CSF (cytokine measurements). Analysis and interpretation of data: BE and ACM (overall data analysis and interpretation), AA (bioinformatics), SR, CL, CSF, ETS, DJL, EJ, YL, RT. Drafting of the manuscript: BE, AA, ACM, RT. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: BE, AA, ACM, CJX, YL. Obtained funding: BE, ACM, KC, CL, EJ, YL, RT. Administrative, technical or material support: All authors. Study supervision: CJX, EJ, YL, RT.

Data availability statement: The data that support the plots within this paper and other findings of this study are available from the corresponding author upon reasonable request. The raw gene expression data, including a sample-data relationship file, as well as the count tables are stored conformant with the MINSEQE reporting standard (Version 1.0, June 2012, accessible at https://zenodo.org/doi/10.5281/zenodo.5706411) at MHH RepoMed repository https://doi.org/10.26068/mhhrpm/20240207-000.

The manuscript was published as a preprint at medRxiv on February 8th 2024 and updated with the revised version on October 15th 2024. The preprint can be accessed at medrxiv.org by entering the manuscript ID MEDRXIV/2024/302515.

Abstract

Background&Aims: The role of antibody-mediated rejection (ABMR) after liver transplantation (LT) remains controversial. Chronic ABMR (cABMR) is often subclinical and potentially missed without surveillance biopsies (svLbx). Transcriptome analysis previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular cABMR signatures after LT.

Methods: We retrospectively identified indication and svLbx from our prospective institutional biorepository (n=1207 over 12 years). We performed RNA-sequencing on liver biopsies (discovery cohort: n=71; validation cohort: n=58). Downstream analyses explored the molecular features of cABMR, clinical (clinTCMR),subclinical TCMR (subTCMR) and chronic ductopenic rejection compared to no histological rejection (NHR).

Results: Nineteen percent of LT recipients with donor-specific antibodies had cABMR. Eighty-one percent of cABMR patients had ALT and AST ≤2x the upper limit of normal, recognized only by svLbx. CABMR was associated with subsequent cirrhosis development in 40%. The cABMR group displayed differentially expressed genes (DEGs) uniquely enriched in fibrogenesis-, complement activation- and TNFα-signaling-related pathways. ClinTCMR showed DEGs uniquely enriched in antigen presentation-, interferon-signaling-, and T cell receptor-signaling-related pathways. Common cABMR and clinTCMR DEGs were enriched in chemokine-signaling- and cytokine response-related pathways. Gene set enrichment scores of interferon-signaling and extracellular matrix remodeling pathways discriminated cABMR and clinTCMR. Molecular signatures of clinTCMR correlated with histological TCMR-patterns. Molecular cABMR-signatures correlated with lobular graft injury and liver

fibrosis scores. SubTCMR was molecularly almost indistinguishable from NHR. There was a high degree of correlation in the DEGs for both the training and validation cohorts.

Conclusions: We report transcriptome-unique features of cABMR that is a unique molecular identity associated with inflammation and fibrogenesis.

Lay summary

Antibody mediated rejection (ABMR) is a rare rejection type after liver transplantation and its chronic form often presents subclinical, i.e. without abnormal liver function test, which may be missed without histological surveillance of the grafts. Nonetheless it is associated with the development of liver cirrhosis in 40% of patients. We performed RNA-sequencing from liver graft biopsies of chronic ABMR, clinical T cell mediated rejection (TCMR), chronic ductopenic rejection and subclinical TCMR and compared these to healthy grafts without signs of graft injury. These analyses revealed cABMR to be associated with TNF-signaling, fibrogenesis and complement activation and cTCMR with interferon-signaling, antigen presentation and T cell receptor-signaling related pathways. These patterns were consistently found in an independent validation cohort. Hence, we firstly report unique transcriptome-features of cABMR discriminating it from all other types of rejection.

Impact and Implications

- Chronic antibody-mediated rejection (ABMR) is a recognized relevant cause of graft injury and unfavorable patient outcomes after kidney, heart and lung transplantation

but the role of chronic ABMR after liver transplantation (LT) remains controversial, despite a recirrhosis rate of 40% in the present study

- We aimed to characterize chronic ABMR after LT on a molecular basis to identify unique features compared to three other rejection entities.

- Our findings highlight chronic ABMR to be a distinct clinical phenotype of rejection after LT. Furthermore, we demonstrate chronic ABMR to present mostly with normal liver enzymes, therefore only being detected if surveillance biopsies are performed for graft monitoring.

- Therefore, our work emphasizes the usage of surveillance graft biopsies for the detection of a fibrosis associated phenotype of chronic ABMR. Pending external validation, the molecular signature may be used in the future to discriminate chronic ABMR from graft injury of other causes.

1. Introduction

Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease, however long term prognosis has not improved in the last decades[1]. Long-term morbidity and mortality are related to sequelae of immunosuppressive drugs and graft dysfunction[1]. Additionally, surveillance liver biopsy (svLBx) programs reveal advanced fibrosis in 20 - 60% of LT recipients (LTR)[2,3].

The existence and relevance of antibody-mediated rejection (ABMR) in AB0⬚compatible LT has been a matter of ongoing debate for decades. Donor specific antibodies (DSA) are associated with increased graft injury, fibrosis, intrahepatic upregulation of transcripts associated with TCMR, and reduced patient and graft survival[4,5]. The prevalence of DSA increases over time by up to 50%. In 2016, the Banff Foundation published the first consensus on acute and chronic ABMR criteria, recognizing ABMR's potential role in LT[6]. The low prevalence of acute and chronic ABMR (cABMR) after LT, probably below 10-15%[6], prevents faster scientific progress in its understanding[7]. ABMR after LT may not elevate liver enzymes, leading to prevalence underestimation without svLBx. Therefore, the true prevalence and the implications of cABMR for LTR are mostly unknown.

Gene expression analysis in graft biopsies fostered the characterization of ABMR, especially after kidney transplantation(KT), revealing similar molecular signatures in heart and lung transplants[8,9], with comparable risk of graft loss irrespective of clinical differences[10]. This retrospective single center study aimed to identify molecular signatures of cABMR in distinction to clinically overt TCMR (clinTCMR), subclinical TCMR (subTCMR) and chronic ductopenic rejection (cDR) in human LT biopsies.

2. Patients and methods

2.1 Patient cohort

Patient samples were retrieved from our ongoing prospective biorepository. The biorepository includes LTR that undergo liver biopsy (LBx) either for the work-up of elevated liver enzymes, liver fibrosis or graft surveillance to individualize immunosuppression[11]. All patients provided written consent.

The study was approved by the local Ethics Committee (protocol number 933 for project Z2 of the comprehensive research center 738; MHH Ethikkommission, Hannover, Germany) and conducted according to the ethical guidelines of the Declarations of Helsinki and Istanbul.

2.2 Liver biopsies, rejection phenotypes, histological grading and staging

Relevant obstructive cholestasis was ruled out by ultrasound examination or MRCP. Biopsies of patients with viral or bacterial infection or vascular complications were excluded. Transcriptome sequencing data was screened for viral sequences (Suppl. Method Section 1.5) but obtained only spurious hits in a small number of the analyzed samples (Suppl. Figure 1), providing no conclusive evidence linking viral infections to liver graft injury. Histological examination and scoring for the rejection activity index (RAI), inflammation grade and fibrosis stage (mHAI score), central perivenulitis, portal microvasculitis, ductular reaction, fatty liver disease and total liver allograft fibrosis (LAF) score was performed by experienced liver pathologists in a blinded fashion[6,12]. Significant fibrosis was defined as: periportal fibrosis (Ishak F) ≥2 and/or any LAF score component ≥2. SubTCMR and clinTCMR were defined as recently published[13]. SubTCMR was defined by a Banff RAI ≥1 + 1 + 1, with transaminases (AST, ALT) and alkaline phosphatase (AP) below two times the ULN

(xULN). ClinTCMR required Banff RAI ≥1 + 1 + 1 and elevated liver enzymes (AST, ALT and/or AP) above two xULN. Possible cABMR was defined per the 2016 Banff criteria[6] as the presence of DSA with a mean fluorescence intensity above 1000, at least moderate fibrosis on histopathological examination and a pattern of liver injury regarded as compatible with cABMR (Banff RAI P subscore ≥1 and/or RAI D subscore ≥1 and Ishak A subscore ≥1 and/or central perivenulitis ≥1 and/or RAI B subscore ≥1) by experienced liver pathologists (BH, DJ) (Figure 1A, suppl. Table 1). Chronic ductopenic rejection (cDR) definition followed the Banff consensus document from 2006[14].

Further information on the materials and methods used are provided in the Supplementary CTAT Table and Supplementary Information file.

3. Results

3.1 Characterization of the training cohort

The liver biopsies of clinTCMR, subTCMR, cABMR and NHR were selected from a cohort of over 1200 liver biopsies taken over 12 years (Figure 1A). All biopsies with available cryo-conserved tissue were included in the discovery cohort (suppl. Figure 2A). The prevalence of cABMR in DSA-positive biopsies was 19% (18/97). Additionally, 19% (18/94) of representative biopsies with advanced fibrosis fulfilled criteria of cABMR.

Patients' samples were grouped by clinical phenotype, the characteristics are outlined in Table 1, suppl. Table 1 and suppl. Figure 4A. There were no age differences between groups (p=0.30) while sex frequency was different (p=0.04). Time after LT was not different between groups in post-hoc testing (suppl. Figure 4A). As per definition, patients with NHR and subTCMR had no elevated liver

enzymes, while those with clinTCMR did. Applying the same threshold of liver enzyme elevation as for clinTCMR and subTCMR, 81% of cABMR had ALT, AST, and AP below two xULN, categorizing them as subclinical and likely to be detected only by svLBx. Histological inflammation and fibrosis were absent in patients with NHR while relevant rejection activity was seen in all other entities being highest in clinTCMR. In contrast, fibrosis according to both Ishak F and LAF scores was highest in cABMR, which also had, by definition, the highest frequency of DSA. Fifty-six percent of biopsies with cABMR exhibited features of TCMR with a RAI ≥1+1+1, similar to ABMR after other solid organ transplantation (SOT)[15,16]. Usage of cyclosporine A (CsA) and tacrolimus (TAC) as primary immunosuppressive drug differed between the groups (p=0.022 and p=0.006 respectively). There were no differences regarding the usage of other immunosuppressive agents between the groups.

3.2 Signature genes of cABMR and clinTCMR are associated with distinct biological processes

The study workflow is highlighted in Figure 1B. To investigate the transcriptome changes in the rejection groups (cABMR, clinTCMR, subTCMR), differential expression analysis of each group compared to NHR was performed in the training cohort (supp. Figure 5; suppl. Table 2).

CABMR and clinTCMR shared 369 up-regulated and 54 down-regulated DEGs, while cABMR had 946 up-regulated and 166 down-regulated unique DEGs, and clinTCMR had 354 up-regulated and 223 down-regulated unique DEGs (Figure 1C; Figure 1D; suppl. Table 4). SubTCMR showed 35 up-regulated and seven down-regulated unique DEGs compared to NHR, including two up-regulated and one down-regulated unique DEGs (Figure 1C).

CABMR up-regulated DEGs were enriched in processes of fibrogenesis and TNF-signaling (hypergeometric test, FDR-adjusted p <0.05) while clinTCMR up-regulated DEGs were associated with processes of allograft rejection and cellular responses to cytokines, especially interferon-signaling (hypergeometric test, FDR-adjusted p <0.05) (suppl. Figure 5A, B; suppl. Table 3). SubTCMR transcriptome profile showed minor difference compared to NHR, with up-regulated DEGs involved in antigen presentation, IL-12 production and dendritic cell differentiation (hypergeometric test, FDR-adjusted p <0.05; suppl. Figure 5C; suppl. Table 3).

Next, we explored the transcriptome changes specific to cABMR and clinTCMR. Unique DEGs in cABMR exhibited enrichment in biological processes of fibrogenesis, cell adhesion and NF-κB-signaling (Figure 2A, B; suppl. Table 5) while unique DEGs in clinTCMR were over-represented in the pathways of allograft rejection, Th1/Th2/Th17 differentiation, antigen processing and presentation, NK cell-mediated cytotoxicity and interferon-signaling among others (Figure 2C, D; suppl. Table 5). To underline the biological relevance of these unique pathways for the pathophysiology of clinTCMR and cABMR, a gene set score enrichment analysis revealed that the positive regulation of response to IFN-gamma was significantly higher in patients with clinTCMR than in patients with cABMR (Student's t-test, p <0.05; Figure 3A). In contrast, the gene set scores for pathways of restructuration of the basement membrane ("Laminin Interactions") and collagen formation ("Collagen chain trimerization") were significantly higher in cABMR than in clinTCMR, both relevant processes to hepatic fibrogenesis (Student's t-test, p=0.008; Figure 3A).

The 369 up-regulated DEGs in both clinTCMR and cABMR, highlighted involvement of TNF receptor non-canonical NF-κB-signaling, chemokine-signaling and cytokine

response to be essential to both clinTCMR and cABMR (suppl. Figure 6; suppl. Tables 6, 7).

3.3 Association of histopathological scores and differentially expressed genes

Next, we linked unique DEGs to histopathological scores that assess liver TCMR (RAI), liver allograft fibrosis (LAF) and inflammatory activity (mHAI) (Figure 3B). RAI was most strongly associated with unique clinTCMR DEGs but only little with unique cABMR DEGs, while cABMR DEGs correlated more with the LAF score and mHAI, underlining the lobular injury pattern in cABMR. Thus, TCMR histopathological patterns (RAI) correlate more with clinTCMR molecular signatures, whereas cABMR signatures correlate with histopathological patterns of fibrosis and lobular injury, indicating distinct molecular signatures and histopathological injury patterns for clinTCMR and aABMR.

3.4 Validation of possible cABMR and clinTCMR gene signature in an independent validation cohort

The clinical features of the validation cohort were mostly consistent with the training cohort (Table 2). Most notably, the time after LT at sampling was longer for all phenotypes than in the training cohort, which was accounted for in the biostatistical analysis (see methods section, suppl. Figure 4B). In contrast to the training cohort, immunosuppressive therapy was comparable between the groups, because TAC became the leading calcineurin inhibitor at our center. CABMR criteria was fulfilled in 13% (7/54) of DSA-positive biopsies and 5% (7/135) of biopsies with advanced fibrosis (suppl. Figure 2B). Again, 50% of cABMR had ALT, AST, and AP below two xULN, therefore being likely to be only detected in svLBx.

Overall consistency of gene expression was high between both cohorts. Eighty-seven percent of cABMR DEGs and 93% of clinTCMR DEGs from the discovery cohort were validated in the validation cohort (Figure 4A). As in the discovery cohort, up-regulated DEGs in cABMR were enriched in processes of fibrogenesis as well as TNF non-canonical NF-κB-signaling (Figure 4B; suppl. Figure 7A, 8A; suppl. Tables 8, 9). Upregulation of fibrogenesis processes and extracellular matrix turnover in cABMR were also confirmed by immunofluorescence staining for COL14A1 and MMP2 (suppl. Figure 9). Up-regulated DEGs in clinTCMR were enriched in pathways of Th1/Th2/Th17 cell differentiation, antigen processing and presentation, T cell receptor-signaling, allograft rejection and innate and adaptive immunity (Figure 4B; suppl. Figure 7B; suppl. Tables 8, 9). There were 23 up-regulated and zero down-regulated DEGs in subTCMR compared to NHR, with enrichment in Th1 and Th2 cell differentiation, interferon-signaling, and cellular response to cytokines (suppl. Figure 7C; suppl. Tables 8, 9). DEGs specific to cABMR showed enrichment in the processes of fibrogenesis, cell adhesion, TNFs binding their physiological receptors, TNFR2 non-canonical NF-κB-signaling and complement and coagulation cascades (suppl. Figure 8B; suppl. Tables 10, 11). DEGs specific to clinTCMR were over-represented in pathways of interferon-signaling, antigen processing and presentation, Th1/2/17 cell differentiation, adaptive immunity, T cell receptor-signaling, IL-2-signaling as well as other pathways related to T cells (suppl. Figure 8C; suppl. Tables 10, 11), with findings from the discovery cohort being largely replicated in the validation cohort. Common DEGs of cABMR and clinTCMR were enriched in pathways including cytokine-signaling, especially interferon-gamma, cell adhesion and allograft rejection (suppl. Figure 10A, B; suppl. Tables 12, 13). All available FFPE samples from patients with cDR (n=4) were included to exclude that cABMR specific DEGs overlap another form of chronic rejection (suppl. Figure 11, suppl.

Table 14 + 15). Only a minority of DEGs were shared between cABMR, clinTCMR and cDR (suppl. Figure 12A). CABMR but not cDR DEGs were overrepresented in pathways of complement cascades and TNF signaling (suppl. Figure 12B, Figure 4B, suppl. Table 16).

3.5 Plasma-soluble immune mediators and serological neoepitope markers of extracellular matrix remodeling

We measured cytokines, complement factors, and markers of extracellular matrix (ECM) remodeling in paired plasma samples (95/121) (suppl. Figure 13).

The 48-cytokine panel showed no significant differences in plasma levels, between the rejection entities (suppl. Figure 14A - 14E), and plasma cytokine levels did not correlate with gene counts for those cytokines (suppl. Figure 15).

ECM markers, C3M and C4M levels were elevated in cABMR compared to NHR (p=0.02 and p<0.01, respectively; suppl. Figure 16B+C), with no differences among other groups. PRO-C3 levels were significantly higher in cABMR and clinTCMR versus subTCMR and NHR, but did not differ between clinTCMR and cABMR (suppl. Figure 16F). There were no differences in median C4G, VICM, PRO-C4, and PRO-C6 levels among the groups (suppl. Figure 16 D, E, G, H).

Finally, C3c and C4 complement median levels did not differ between groups (suppl. Figure 17).

3.6 Outcomes

The follow-up periods for NHR (59 (5 – 178) months), subTCMR (60 (6 – 164) months), clinTCMR (44 (23 – 170) months), cABMR (74 (24 – 170) months), and cDR (34 (6 – 167) months) were not significantly different (p = 0.67).

At the last follow-up, none of the NHR patients, 12% of those with subTCMR, and five percent with clinTCMR had developed cirrhosis. The cirrhosis prevalence was 50% in cDR and 40% in cABMR, with significance between NHR and cABMR (p=0.03), and NHR and cDR (p=0.01). No differences in survival and retransplantation were observed (Log-Rank, p=0.77).

4. Discussion

In this study, molecular signatures of four different rejection entities, clinTCMR, cABMR, subTCMR and cDR, were characterized using whole-transcriptome sequencing methodologies (mRNA from fresh frozen and FFPE liver biopsies) in two independent cohorts. We systemically previewed how common and unique features of all four rejection phenotypes highlight potential pathophysiological commonalities and differences. We provide evidence for cABMR to be pathophysiologically distinct from clinTCMR, mainly by fibrogenic processes, by TNF-signaling via NF-κB as well as complement activation. Lastly, we demonstrated plausibility by linking the molecular phenotype of clinTMCR to hallmark genes of T cell⬜mediated signaling and to typical histological TCMR patterns by a correlation with the RAI. Likewise, the molecular phenotype of cABMR was associated with genes of fibrogenesis, and histological features of lobular hepatitis and liver fibrosis by a correlation with the HAI and with the LAF score. Of note, in a rat model of ABMR after LT DEGs enriched in pathways of TNF-signaling via NF-κB were more abundant in ABMR[17].

Various attempts were made to derive a gene signature of clinTCMR in LTR by using a microarray gene expression approach[4,18,19]. Most recently, an 11-gene signature showed an excellent diagnostic performance to discriminate clinTCMR from NHR[18]. Ten out of eleven (all but *HLA-DMA*) of these DEGs were significantly up-

regulated in clinTCMR compared to NHR in our discovery cohort while 4/11 were up-regulated in the smaller validation cohort (*CXCL9, TOP2A, GPNMB, PLA2G7*). Of these, only *PLA2G7,* a gene encoding for a phospholipase that inactivates platelet-activating factor, was uniquely associated with clinTCMR but not with other rejection phenotypes in our study. The low concordance of the 11-gene set with the unique transcriptome patterns of clinTCMR described here underlines the importance of a comprehensive approach including all rejection types for the identification of transcriptomic modules shared by different rejection types and rejection type-specific pathways.

The multicenter INTERLIVER study could not identify ABMR-specific signatures in a cohort of 235 prospectively collected LBx[20][20]. This probably relates to the mostly missing DSA testing in the participating centers and the low percentage of svLBx (15%) in this study. The current study selected 22 cABMR cases out of 1207 LBx over a period of 12 years and up to 81% of cABMR had no relevant elevation of liver enzymes and would have been missed without svLBx. Nonetheless, cABMR was associated with a high rate of cirrhosis development (40%) despite a first diagnosis in a subclinical state. Of the top ten genes that were most strongly associated with clinTCMR in the INTERLIVER study[20], 8/10 (all but *PSMB8* and *PSMB10*) and 6/10 (*GBP1, GBP5, CXCL9, STAT1, PSMB9* and *TAP1*) were significantly overexpressed in clinTCMR in our discovery and validation cohort, respectively. Two genes (*GBP1* and *PSMB9*) from the INTERLIVER study were uniquely associated with clinTCMR in our cohort, both of which are interferon-inducible. Comparison of published literature with our study highlights that gene array-based classifiers do not necessarily quantify features unique to clinTCMR but those that may be shared with other rejection phenotypes, e.g. cABMR, in highly selected, and phenotypically well-characterized cohorts without prevalent ABMR cases. Hence, the final clinical use case of such

classifiers will be determined in an unbiased real-world scenario pending further validation. Differences in DEGs between our cohort and previous literature may also be related to different techniques to quantify gene expression (gene array in the INTERLIVER study and mainly in studies of the Sanchez-Fueyo group[18,20,21] vs. whole-transcriptome sequencing in the present study). While it was shown that the number of genes varies between technological platforms, biological processes as well as the performance of diagnostic classifiers were consistent across platforms in patients after KT[22]. It was further demonstrated in comparative RNA-sequencing analyses that the correlation of mapped reads was excellent between RNA extracted from fresh-frozen tissue and FFPE tissue, although RNA gets degraded with FFPE conservation[23,24].

Concerning cABMR, deposition of complement C4d is regarded as a key feature for the histopathological suspicion of ABMR[6]. However, it is acknowledged that the performance of various assays to stain C4d is heterogeneous, dependent on the technique and the protocol of the local center[6]. Staining for C4d on FFPE liver tissue exhibits acceptable performance in acute ABMR in comparison to the gold standard of immunofluorescence on frozen tissue, but data on assay performance in cABMR is lacking[25]. However, it is widely acknowledged that the sensitivity of C4d staining for cABMR is generally low[6]. Also, C4d deposition may occur in case of biliary obstruction, viral infection of the liver or autoimmune liver injury[6] thereby reducing specificity. Given the methodological pitfalls of C4d staining, we included patients with possible cABMR and not only with probable cABMR as defined by the current 2016 Banff consensus[6]. Additionally, diagnosing cABMR in the absence of C4d deposition is well established also after KT or lung transplantation with the same prognostic implications as C4d positive ABMR[26,27]. The consistency of the

molecular phenotype found for cABMR in the present study and in published studies from KT supports the validity of our approach[28]. Hence, our findings fit current pathophysiological concepts of ABMR derived from other SOT, add evidence in favor of the existence of cABMR after LT[29].

We report two independent cohorts from our center that are separated by time (discovery cohort: 2008 – 2016, validation cohort 2018 – 2022). Within this 14 years immunosuppression regimen changed to predominantly tacrolimus based regimen with putatively lower cABMR rates with tacrolimus. A further limitation is that most liver biopsies in the validation cohort (cABMR, subTCMR but also NHR as controls) were taken later after LT than in the discovery cohort which we tried to adjust for in the analysis. In addition, different material with different qualities of RNA was used in these cohorts (discussed above), but we can still demonstrate biological consistency as evidenced by highly overlapping pathways between both cohorts for clinTCMR and cABMR. The molecular profile in terms of biological processes of cABMR was largely maintained in the validation cohort, despite lower sample numbers for cABMR. Despite a recruiting phase of 14 years and a biorepository of over 1200 biopsies, a general limitation of the current study is the low sample number of cABMR and even more so for cDR, which was for the very same reason not the focus of this study. Consistency of our findings with the published literature on clinTCMR after LT as well as the excellent correlation of data derived from differently conserved tissue with different methodologies of sequencing as discussed above underlines that the necessary validation of our findings can also be performed from stored samples rather than from fresh frozen LBx facilitating external multicenter validation. However, a reasonable amount of cABMR may be missed in such studies if svLBx and DSA testing were not performed routinely as up to 81% of cABMR in our

cohort had liver enzymes below two xULN and would not be eligible for liver biopsy in studies that do not incorporate svLBx[30]. We highlight biological processes of cABMR taking place in LTR that may provide druggable targets in the future to prevent disease progression. Concerning the latter, implementation of svLBx programs[3,11] will probably be a relevant prerequisite to determine the real prevalence of cABMR across countries, centers, and immunosuppression regimens. The broader application of DSA measurement and elastography for the assessment of graft fibrosis can help to enrich for LTR with relevant graft injury [2,31]. In case of relevant fibrosis or positivity for DSA, a biopsy is often warranted. However, a subsequent re-cirrhosis rate of 40% in cABMR might justify a svLBx in all LTR with DSA and even more so in LTR with DSA and elevated liver stiffness measurements even when liver function tests are normal. Apart from markers of extracellular matrix remodeling, which are known to be associated with liver graft fibrosis[32], neither complement nor cytokine levels in the peripheral blood could mirror the graft injury in the liver. Unfortunately, the blood was not representative for the T cell compartment in the liver itself[33–35], underlining the need for svLBx to understand local immune regulation in the graft.

This study indicates cABMR after LT as a unique entity with a similar gene signature as described in other SOT. The distinct phenotype of cABMR after LT is characterized by fibrogenesis, and TNF-mediated signaling via NF-κB and involves endothelial cell-signaling as well as complement cascades. The cABMR gene signature is closely associated with histological fibrosis (LAF score) and is frequently detected in DSA-positive LTR. Pending external validation, we highlight a possible application of RNA-sequencing on liver biopsies to facilitate the detection of cABMR in LTR.

Acknowledgements:

We thank Szilvia Ziegert and Konstantinos Iordanidis from the "immune tolerance working group" at Hannover Medical School for technical assistance. We thank Esma Turlak for assistance with immunofluorescent staining. We thank Stefan Huebscher, already retired from his work in the pathology department of the University of Birmingham/UK, for his advice in initiating this project and for his training of the pathologists at Hannover Medical School during a fruitful workshop in September 2016.

References

[1]   Rana A, Ackah RL, Webb GJ, Halazun KJ, Vierling JM, Liu H, et al. No Gains in Long-term Survival After Liver Transplantation Over the Past Three Decades. Ann Surg 2019;269:20–7. https://doi.org/10.1097/SLA.0000000000002650.

[2]   Höfer A, Jonigk D, Hartleben B, Verboom M, Hallensleben M, Manns MP, et al. Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. Sci Rep 2020;10:14242. https://doi.org/10.1038/s41598-020-70938-7.

[3]   Rocque B, Zaldana A, Weaver C, Huang J, Barbetta A, Shakhin V, et al. Clinical Value of Surveillance Biopsies in Pediatric Liver Transplantation. Liver Transplant 2022;28:843–54. https://doi.org/10.1002/lt.26399.

[4]   Londoño M-CC, Souza LN, Lozano J-JJ, Miquel R, Abraldes JG, Llovet L-PP, et al. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. J Hepatol 2018;69:626–34. https://doi.org/10.1016/j.jhep.2018.04.012.

[5]   Kim PTW, Demetris AJ, O'Leary JG, O'Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis.' Curr Opin Organ Transplant 2016;21:209–18. https://doi.org/10.1097/MOT.0000000000000275.

[6]   Demetris AJ, Bellamy C, Hübscher SG, O'Leary J, Randhawa PS, Feng S, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016;16:2816–35. https://doi.org/10.1111/ajt.13909.

[7]   Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Huyen J-PD, Mooney N, et al. Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. N Engl J Med 2013;369:1215–26. https://doi.org/10.1056/NEJMoa1302506.

[8]   Gauthier PT, Mackova M, Hirji A, Weinkauf J, Timofte IL, Snell GI, et al. Defining a natural killer cell-enriched molecular rejection-like state in lung transplant transbronchial biopsies. Am J Transplant 2023;23:1922–38. https://doi.org/10.1016/j.ajt.2023.06.003.

[9]   Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, et al. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. Am J Transplant 2017;17:2851–62. https://doi.org/10.1111/ajt.14329.

[10] Halloran PF, Madill-Thomsen KS, Pon S, Sikosana MLN, Böhmig GA, Bromberg J, et al. Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes. Am J Transplant 2022;22:1976–91. https://doi.org/10.1111/ajt.17092.

[11] Saunders EA, Engel B, Höfer A, Hartleben B, Vondran FWRR, Richter N, et al. Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. Am J Transplant 2022;22:519–31. https://doi.org/10.1111/ajt.16817.

[12] Venturi C, Sempoux C, Bueno J, Ferreres Pinas JC, Bourdeaux C, Abarca-Quinones J, et al. Novel Histologic Scoring System for Long-Term Allograft Fibrosis After Liver Transplantation in Children. Am J Transplant 2012;12:2986–96. https://doi.org/10.1111/j.1600-6143.2012.04210.x.

[13] Höfer A, Jonigk D, Hartleben B, Verboom M, Hallensleben M, Hübscher SG, et al. DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection. Transplantation 2020;104:551–61. https://doi.org/10.1097/TP.0000000000003034.

[14] Demetris AJ. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489–501. https://doi.org/10.1002/hep.21280.

[15] Nickerson PW. What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation? Am J Transplant 2020;20:12–22. https://doi.org/10.1111/ajt.15859.

[16]   Fedrigo M, Berry GJ, Coutance G, Reed EF, Lin C-Y, Giarraputo A, et al. Report of the 2022 Banff Heart Concurrent: Focus on non-human leukocyte antigen antibodies in rejection and the pathology of "mixed" rejection. Am J Transplant 2023. https://doi.org/10.1016/j.ajt.2023.10.004.

[17]   Tajima T, Hata K, Kusakabe J, Miyauchi H, Badshah JS, Kageyama S, et al. Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats. Front Immunol 2023;14:1–17. https://doi.org/10.3389/fimmu.2023.1186653.

[18]   Vionnet J, Miquel R, Abraldes JG, Wall J, Kodela E, Lozano J-J, et al. Non-invasive alloimmune risk stratification of long-term liver transplant recipients. J Hepatol 2021;75:1409–19. https://doi.org/10.1016/j.jhep.2021.08.007.

[19]   **Bonaccorsi-Riani E, Pennycuick A**, Londoño M-CC, Lozano J-JJ, Benítez C, Sawitzki B, et al. Molecular Characterization of Acute Cellular Rejection Occurring During Intentional Immunosuppression Withdrawal in Liver Transplantation. Am J Transplant 2016;16:484–96. https://doi.org/10.1111/ajt.13488.

[20]   Madill-Thomsen K, Abouljoud M, Bhati C, Ciszek M, Durlik M, Feng S, et al. The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study. Am J Transplant 2020;20:2156–72. https://doi.org/10.1111/ajt.15828.

[21]   Madill-Thomsen KS, Abouljoud M, Bhati C, Ciszek M, Durlik M, Feng S, et al. The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. Am J Transplant 2022;22:909–26. https://doi.org/10.1111/ajt.16890.

[22]   **Kurian SM, Velazquez E**, Thompson R, Whisenant T, Rose S, Riley N, et al. Orthogonal Comparison of Molecular Signatures of Kidney Transplants With Subclinical and Clinical Acute Rejection: Equivalent Performance Is Agnostic to Both Technology and Platform. Am J Transplant 2017;17:2103–16. https://doi.org/10.1111/ajt.14224.

[23]   Bossel Ben-Moshe N, Gilad S, Perry G, Benjamin S, Balint-Lahat N, Pavlovsky A, et al. mRNA-seq whole transcriptome profiling of fresh frozen versus archived fixed tissues. BMC Genomics 2018;19:419. https://doi.org/10.1186/s12864-018-4761-3.

[24]   Jacobsen SB, Tfelt-Hansen J, Smerup MH, Andersen JD, Morling N. Comparison of whole transcriptome sequencing of fresh, frozen, and formalin-fixed, paraffin-embedded cardiac tissue. PLoS One 2023;18:e0283159. https://doi.org/10.1371/journal.pone.0283159.

[25]   Neil DAH, Bellamy CO, Smith M, Haga H, Zen Y, Sebagh M, et al. Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue. Hum Pathol 2018;73:144–55. https://doi.org/10.1016/j.humpath.2017.12.007.

[26]   Orandi BJ, Alachkar N, Kraus ES, Naqvi F, Lonze BE, Lees L, et al. Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation. Am J Transplant 2016;16:213–20. https://doi.org/10.1111/ajt.13434.

[27]   Aguilar PR, Carpenter D, Ritter J, Yusen RD, Witt CA, Byers DE, et al. The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation. Am J Transplant 2018;18:936–44.

https://doi.org/10.1111/ajt.14534.

[28] **Kong F, Ye S**, Zhong Z, Zhou X, Zhou W, Liu Z, et al. Single-Cell Transcriptome Analysis of Chronic Antibody-Mediated Rejection After Renal Transplantation. Front Immunol 2022;12:1–17. https://doi.org/10.3389/fimmu.2021.767618.

[29] Loupy A, Lefaucheur C. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med 2018;379:1150–60. https://doi.org/10.1056/NEJMra1802677.

[30] Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol 2021;75:1203–16. https://doi.org/10.1016/j.jhep.2021.07.027.

[31] Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis. PLoS One 2017;12:e0185192. https://doi.org/10.1371/journal.pone.0185192.

[32] Engel B, Falk Villesen I, Fisker Nielsen MJ, Karsdal M, Taubert R, Jaeckel E, et al. Quantification of extracellular matrix remodeling for the non-invasive identification of graft fibrosis after liver transplantation. Sci Rep 2023;13:6103. https://doi.org/10.1038/s41598-023-33100-7.

[33] Taubert R, Pischke S, Schlue J, Wedemeyer H, Noyan F, Heim A, et al. Enrichment of regulatory T Cells in acutely rejected human liver allografts. Am J Transplant 2012. https://doi.org/10.1111/j.1600-6143.2012.04264.x.

[34] Baumann AK, Schlue J, Noyan F, Hardtke-Wolenski M, Lehner F, Barg-Hock H, et al. Preferential accumulation of T helper cells but not cytotoxic T cells

characterizes benign subclinical rejection of human liver allografts. Liver

Transplant 2016. https://doi.org/10.1002/lt.24427.

[35] Mederacke Y-S, Nienen M, Jarek M, Geffers R, Hupa-Breier K, Babel N, et al.

T cell receptor repertoires within liver allografts are different to those in the

peripheral blood. J Hepatol 2021;74:1167–75.

https://doi.org/10.1016/j.jhep.2020.12.014.

Bold designates equally contributing authors in the references.

Abbreviations: ABMR: antibody-mediated rejection; cABMR: chronic antibody-mediated rejection; cDR: chronic ductopenic rejection; CsA: cyclosporine A; clinTCMR: clinically overt T cell-mediated rejection; DEGs: differentially expressed genes; DSA: donor-specific anti-HLA antibodies; FDR: false-discovery rate; FFPE: formalin-fixed paraffin-embedded; KT: kidney transplantation; LAF: liver allograft fibrosis; LBx: liver graft biopsy; LT: liver transplantation; LTR: liver transplant recipient; NHR: no histological rejection; mHAI: modified histological activity index; RAI: rejection activity index; RIN: RNA integrity number; SOT: solid organ transplantation; subTCMR: subclinical T cell-mediated rejection; svLBx: surveillance liver graft biopsies; TAC: tacrolimus; TCMR: T cell-mediated rejection; ULN: upper limit of normal; x ULN: times the upper limit of normal.

Tables

Table 1	Overall	NHR	subTCMR	cABMR	clinTCMR	p
sample number	71	18	26	16	11	
age [years]	52 (18 – 76)	50 (20 – 69)	52 (21 – 67)	59 (22 – 67)	47 (18 – 76)	0.30

female sex	24 (33.8)	8 (44.4)	5 (19.2)	4 (25.0)	7 (63.6)	0.04
time after LT[months]	13 (2 – 298)	10 (5 – 60)	19 (5 – 116)	32 (6 – 298)	7 (2 – 152)	0.04
AST [xULN]	0.8 (0.3 – 11.9) (n = 70)	0.6 (0.4 – 0.8) (n = 17)	0.7 (0.3 – 1.2)	0.9 (0.5 – 1.6)	3 (1.5 – 11.9)	< 0.001
ALT [xULN]	0.5 (0.1 – 17.2)	0.4 (0.2 – 0.6)	0.5 (0.1 – 1.5)	0.5 (0.3 – 2.1)	4.1 (2.4 – 17.2)	< 0.001
AP [xULN]	0.9 (0.2 – 3.9) (n = 62)	0.7 (0.2 – 1.1) (n = 14)	0.8 (0.2 – 1.3)	1.2 (0.7 – 3.1)	1.8 (0.8 – 3.9)	< 0.001
bilirubin [xULN]	0.5 (0.2 – 2.5)	0.5 (0.2 – 2.5)	0.5 (0.2 – 1.5)	0.6 (0.2 – 2.2)	0.9 (0.3 – 2.5)	0.02
RAI	3 (0 – 8)	0 (0 – 1)	3.5 (3 – 6)	3.5 (1 – 8)	5 (3 – 7)	< 0.001
mHAI	3 (0 – 8)	1 (0 – 2)	2 (0 – 8)	5 (2 – 7)	4 (2 – 6)	< 0.001
Ishak fibrosis stage	1 (0 – 6)	0 (0 – 1)	1 (0 – 4)	2.5 (1 – 6)	1 (0 – 2)	< 0.001
LAF Score	1 (0 – 8)	0 (0 – 1)	1 (0 – 5)	4 (2 – 8)	1 (0 – 3)	< 0.001
DSA positive	28 (39.4)	1 (5.6)	7 (26.9)	16 (100)	4 (36.4)	< 0.001
TAC	25 (35.2)	10 (55.6)	10 (38.5)	0 (0.0)	5 (45.5)	0.006
CsA	44 (62.0)	8 (44.4)	15 (57.7)	15 (93.8)	6 (54.5)	0.022
Sirolimus	1 (1.4)	0 (0.0)	0 (0.0)	1 (6.3)	0 (0.0)	0.32
Prednisolone	57 (80.3)	13 (72.2)	21 (80.8)	12 (75.0)	1 (100)	0.29
Mycophenolate-mofetil	63 (88.7)	15 (83.3)	24 (92.3)	15 (93.8)	9 (81.8)	0.62
Azathioprine	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (9.1)	0.14

Continuous variables reported as median (range), categorical variables as number (frequency).

Table 2	Overall	NHR	subTCMR	cABMR	clinTCMR	p
sample number	58	20	20	6	12	
age [years]	49.5 (19 - 75)	50 (19 - 74)	49.5 (19 - 67)	57.5 [19 - 75]	35.0 (25 - 67)	0.51
female sex	17 (29.3)	7 (35.0)	6 (30.0)	3 (50.0)	1 (8.3)	0.25
time after LT [months]	77 (1.0 - 276.0)	83 (10 - 257)	77 (13 - 198)	149 (80 - 276)	14 (1 - 189)	0.003
AST [xULN]	0.8 (0.3 - 26.1)	0.7 (0.4 - 1.1)	0.7 (0.3 - 2.0)	1.3 (0.7 - 7.1)	3.1 (0.6 - 26.1)	<0.001
ALT [xULN]	0.6 (0.2 - 46.3)	0.4 (0.2 - 0.9)	0.6 (0.3 - 1.7)	0.5 (0.3 - 11.0)	3.9 (1.0 - 46.3)	<0.001

AP [xULN]	0.9 (0.4 - 9.4)	0.6 (0.4 - 1.1)	0.7 (0.5 - 1.6)	1.4 (0.5 - 3.5)	2.9 (1.2 - 9.4)	<0.001
bilirubin [xULN]	0.5 (0.2 - 3.5)	0.4 (0.2 - 1.3)	0.5 (0.2 - 1.5)	0.6 (0.3 - 2.1)	1.2 (0.4 - 3.5)	0.002
RAI	3 (0 - 7)	0 (0 - 1)	3 (3 - 5)	1 (1 - 4)	5 (3 - 7)	<0.001
mHAI	3 (0 - 12)	1 (0 - 1)	3 (1 - 6)	5 (2 - 8)	4 (2 - 12)	<0.001
Ishak fibrosis stage	1 (0 - 5)	0 (0 - 1)	1 (0 - 1)	3 (2 - 5)	0 (0 - 2)	<0.001
LAF score*	1 (0 - 6)*	1 (0 - 1)*	1 (0 - 2)*	4 (2 - 6)*	2 (0 - 2)*	0.008
DSA positive**	10 (18.9)**	1 (6.7)**	2 (10.0)	6 (100.0)	1 (8.3)	<0.001
TAC	43 (74.1)	15 (75.0)	16 (80.0)	3 (50.0)	9 (75.0)	0.53
CsA	13 (22.4)	5 (25.0)	3 (15.0)	3 (50.0)	2 (16.7)	0.33
Sirolimus	7 (12.1)	4 (20.0)	1 (5.0)	0 (0.0)	2 (16.7)	0.36
Prednisolone	25 (43.1)	5 (25.0)	8 (40.0)	3 (50.0)	9 (75.0)	0.049
Mycophenolate-mofetil	47 (81.0)	15 (75.0)	16 (80.0)	6 (100.0)	10 (83.3)	0.59
Azathioprine	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	NA
LAF score available:26/58(NHR 11/20. subTCMR 3/20. cABMR 4/6. clinTCMR 8/12)						
**DSA available:53/58(NHR 15/20)						

Continuous variables reported as median (range), categorical variables as number (frequency).

Figure legends

Figure 1: Study design and molecular differences between the rejection groups

(A) Flow Chart highlighting the diagnostic process for phenotypical characterization of rejection. **(B)** Study design. **(C)** Venn diagram showing the numbers of the up-regulated and down-regulated DEGs in each rejection group compared to NHR. **(D)** Heatmap of scaled gene count. Rows are unique DEGs of cABMR and clinTCMR. columns represent samples. clinTCMR: clinical T cell-mediated rejection; cABMR: chronic antibody-mediated rejection; subTCMR: subclinical T cell-mediated rejection; NHR: no histological rejection, DEGs: differentially expressed genes.

Figure 2: Molecular signature and functional enrichment of unique DEGs of cABMR and clinTCMR

(A) Volcano plot showing the unique cABMR vs NHR DEGs (p-value adjusted by false discovery rate (FDR) <0.05, absolute $\log_2$ fold change (LogFc) > 1). **(B)** Over-represented pathways out of DEGs in panel A. **(C)** Volcano plot showing unique clinTCMR vs NHR DEGs (FDR <0.05, LogFc >1) **(D)** Over-represented pathways out of DEGs in panel C. clinTCMR: clinical T cell-mediated rejection; cABMR: chronic antibody-mediated rejection; subTCMR: subclinical T cell-mediated rejection; NHR: no histological rejection, DEGs: differentially expressed genes.

Figure 3: Gene set enrichment analysis and gene count association with histological scores

(A) Gene set scores of three selected pathways discriminate cABMR and clinTCMR. *: p <0.05, **: p <0.01; Student's t-test. **(B)** Association of unique DEGs of cABMR and clinTCMR with three histopathological scores. $\log_{10}$(FDR) on the y-axis is signed by the correlation fold change, while DEGs are ranked on the x axis by the association t-stat value. clinTCMR: clinical T cell-mediated rejection; cABMR: chronic antibody-mediated rejection; subTCMR: subclinical T cell-mediated rejection; NHR: no histological rejection, DEGs: differentially expressed genes.

Figure 4: Validation of DEGs and functional pathways: (A) Validation of rejection vs NHR DEGs. DEGs with nominal significance (p <0.05) in the validation cohort are plotted**. (B)** Over-represented pathways out of DEGs in panel A. clinTCMR: clinical T cell-mediated rejection; cABMR: chronic antibody-mediated rejection; subTCMR: subclinical T cell-mediated rejection; NHR: no histological rejection, DEGs: differentially expressed genes.

Figure 1

(A)

	Exclusion of other causes (e.g. infections, acute cholestasis)			
DSA:	+/- DSA			MFI >1000
Liver enzymes (AST, ALT, ALP)	≤ ULN	<2x ULN	≥2x ULN	any
Histology (22 criteria)	RAI ≤1	RAI ≥1+1+1	RAI ≥1+1+1	suggestive for cABMR
	⇩ NHR	⇩ subTCMR	⇩ clinTCMR	⇩ cABMR

(B)

	cABMR	clinTCMR	subTCMR	NHR
DISCOVERY	16	11	26	18
VALIDATION	6	12	20	20

liver graft biopsy (LBx)

RNA isolation and library construction

Sequencing

(C)

Up-regulated vs. NHR

cABMR   clinTCMR

946 (56.2%)   347 (20.6%)   354 (21.0%)

22 (1.3%)

10 (0.6%)   1 (0.1%)

2 (0.1%)

subTCMR

Down-regulated vs. NHR

cABMR   clinTCMR

166 (37.1%)   51 (11.4%)   223 (49.9%)

3 (0.7%)

3 (0.7%)   0 (0.0%)

1 (0.2%)

subTCMR

(D)

Condition

>1

Scaled count score

<-1

cABMR vs NHR DEGs
- Up-regulated
- Down-regulated

clinTCMR vs NHR DEGs
- Up-regulated
- Down-regulated

Condition
- cABMR
- clinTCMR
- subTCMR
- NHR

Figure 2

(A)

(B)

(C)

(D)

Figure 3

(A)

(B)

RAI

LAF

mHAI

Figure 4

(A)

(B)